Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK) is gaining ground after beating estimates and raising guidance, but persistent investor apathy could limit gains.

Merck (MRK) Trading Higher After Strong Q3 Earnings

Merck early Tuesday reported better-than-expected third-quarter earnings and sales and slightly raised its guidance. The post Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes Guidance appeared first on Investor's Business Daily.

Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes Guidance

The Kenilworth, New Jersey, company on Tuesday reported a profit of $1.16 per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to $1.74 per share.

Strong sales of drugs, vaccines, propel Merck in third quarter

Bristol-Myers

These drugmakers are proof that reinvesting in pipeline projects pays off in the long run.

These 2 Pharmas Have Made Their Pipelines a Competitive Advantage

Merck & Co Inc on Tuesday reported a 54.7% rise in third-quarter profit, helped by strong sales of blockbuster cancer drug Keytruda and rebound in sales of its key drugs.

Merck quarterly profit rises nearly 55% as key drug sales rebound

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2020 Financial Results

Merck Announces Third-Quarter 2020 Financial Results

Although there are still many challenges and issues to be resolved with this area of technology, it may potentially be a way to one day address critical access-to-care issues.

Merck Is Piloting A Drone Delivery Program For Medications

Apple

Amazon

Ford Motor Company

Alphabet

Microsoft

Starbucks

Twitter

Big Techs to Report Earnings Results This Week.

Big Techs to Report Earnings Results This Week

Caterpillar

Cross Country Healthcare

Cisco Systems

Honeywell

HarborOne Bancorp

Intel

Johnson & Johnson

Procter & Gamble

UnitedHealth Group

Walmart

Two new sample breakout stocks for Week 44 with better than 10% short-term upside potential. Now up an average +242.9% YTD. Last week gains peaked with PSTI +12.6% and ORTX +9.7% in less than five days before selections pulled back with the market to returns at the close of -2.2%.

Week 44 MDA Breakout Forecast - October: Short-Term Picks To Give You An Edge

AbbVie

Enterprise Products Partners

Gladstone Investment

Lockheed Martin

LTC Properties

Main Street Capital

MetLife

Realty Income Corp

People's United Financial

Prudential Financial

Shaw Communications

Unum

Exxon Mobil

From May to July, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five 'outstanding dividend' articles revealed 56 dividend equities. The 52 select-stocks plus 4 funds ranged from 0.48% to 10.49% in annual yield and ranged from -2.98% to 52.53% in one-year price-target-upsides per brokers 10/21/20.

13 Of 56 Outstanding Dividend Stocks Stand Tall For November

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020

Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merck posted positive Phase 3 clinical trials results for a pneumococcal vaccine candidate and said it remains on track to apply for U.S. FDA approval this year. MRK stock edged higher.

Merck Posts Positive Data For Pneumococcal Vaccine Candidate, Eyes Approval

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results from 2 Ph3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

Merck (MRK) closed the most recent trading day at $78.67, moving -1.45% from the previous trading session.

Merck (MRK) Stock Moves -1.45%: What You Should Know

GlaxoSmithKline

Seagen

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Channeladvisor

McDonald's

NIKE

Pluristem Therapeutics

Two new sample breakout stocks for Week 43 with better than 10% short-term upside potential. Now up an average +241.2% YTD.

Week 43 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Colgate-Palmolive

Costco

General Dynamics

Medtronic

PepsiCo

10 Dividend Growth Stocks For October 2020

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Three-Year Survival Data for KEYTRUDA® in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab

Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer

The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.

Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma

Korea Electric Power

Momo

Verso

While the coronavirus has brought excitement back to the markets, it’s the contrarian who is eyeballing value stocks that stands to win in the long run. The post 7 Value Stocks To Buy in an Overvalued Market appeared first on InvestorPlace.

7 Value Stocks To Buy in an Overvalued Market

DARMSTADT, Germany, Oct. 15, 2020 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that Dr. Luciano Rossetti, MD, will be retiring as Global Head of Research & Development (R&D) for the Healthcare business sector. Dr. Rossetti will...

News for Merck Stock (MRK)